[1]Patent:EP1666463,2006,A1.Locationinpatent:Page/Pagecolumn13-15
[2]Patent:EP1666463,2006,A1.Locationinpatent:Page/Pagecolumn12-13
[3]Patent:EP1666463,2006,A1.Locationinpatent:Page/Pagecolumn10-12
[4]Patent:US2002/128480,2002,A1
[5]Patent:US2007/37854,2007,A1.Locationinpatent:Page/Pagecolumn4-5
[6]Patent:US2007/37854,2007,A1.Locationinpatent:Page/Pagecolumn6
[1]Patent:US2004/18192,2004,A1
Title: Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.
Journal: The AAPS journal 20110601
Title: Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110101
Title: Small molecule integrin antagonists in cancer therapy.
Journal: Mini reviews in medicinal chemistry 20091001
Title: Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.
Journal: Investigational new drugs 20090401
Title: Integrins: molecular targets in cancer therapy.
Journal: Current oncology reports 20060301
Title: An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040215
Title: Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
Journal: Cancer research 20021101
Title: Funahashi Y, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res. 2002;62(21):6116-6123.
Title: Ito K, et al. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Cancer Sci. 2014;105(8):1023-1031.
